[The amplification of c-myc, N-ras, c-erb B oncogenes in ovarian malignancies].
In this study, [a-32p]dATP labelled probes of c-myc, N-ras and c-erb B genes were employed to perform dot blot hybridisation with DNA extracted from 17 cases of primary ovarian cancer, 3 cases of recurrent ovarian cancer, 2 cases of germ cell ovarian cancer, 5 cases of serous cysadonoma and 4 cases of normal ovarian tissue. Some specimens were examined by Southern blot hybridisation. The results showed varying degrees of amplification: c-myc 54.5%, N-ras 64.1% and c-erb B 31.8%, in the 22 cases of ovarian malignancies. All were significantly higher than in the three benign tumours and in normal ovarian tissue. Frequency of amplification of more than 2 oncogencis at the same time was found to be 40.9%. There was a negative correlation between amplification of c-myc and differentiation. A relatively high amplification of N-ras was present in late stage ovarian cancer. Patients with c-erb B amplification showed a shorter survival period than those without amplification.
Xin
X Y
XY
Xi Jing Hospital, Fourth Military University, Xi'an.
D000230:Adenocarcinoma / Q000235:genetics; D018293:Cystadenoma, Serous / Q000235:genetics; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D005784:Gene Amplification; D016259:Genes, myc; D011905:Genes, ras; D006801:Humans; D015151:Immunoblotting; D009373:Neoplasms, Germ Cell and Embryonal / Q000235:genetics; D010051:Ovarian Neoplasms / Q000235:genetics*; D011518:Proto-Oncogene Proteins / Q000235:genetics*
D011518:Proto-Oncogene Proteins; D066246:ErbB Receptors